hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06315816, orgStudyIdInfo id: DokuzEU-1, briefTitle: Virtual Reality Used During Tooth Extraction and Extirpation Treatment, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2024-09-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Murat Bektaş, class: OTHER, descriptionModule briefSummary: This study carriy out to evaluate the effect of virtual reality glasses used during tooth extraction and extirpation treatment under local anesthesia on anxiety and fear in children aged 7-10 years., conditionsModule conditions: Anxiety and Fear, conditions: Tooth Disease, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The population will consist of children between the ages of 7-10 who presented to the pediatric dental clinic of an oral and dental health center Turkey. The sample size of the study was calculated as GPOWER 3.1 statistical analysis software, based on a significance level of 0.05, a power value of 80%, and an effect size of 0.15 (medium effect size). Considering 10% attrition, it will plan to sample a total of 80 children, including 40 in the experimental group and 40 in the control group. Eventually, a total of 120 children, 60 in the experimental group and 60 in the control group,will include in the study to reveal the relationship between the variables more clearly., primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, maskingDescription: The data will be analyzed by a statistician blind to the groups., whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: virtual reality glasses used during tooth extraction and extirpation treatment, outcomesModule primaryOutcomes measure: Anxiety Means, primaryOutcomes measure: Fear Means, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Hakkari University, status: RECRUITING, city: Hakkari, state: Merkez, country: Turkey, contacts name: Dilek Demir Kösem, PhD, role: CONTACT, phone: +9005534813290, email: dilekdemir624@gmail.com, geoPoint lat: 37.57444, lon: 43.74083, locations facility: Hakkari University, status: RECRUITING, city: Hakkari, country: Turkey, contacts name: Dilek Demir Kösem, PhD, role: CONTACT, phone: +9005534813290, email: dilekdemir624@gmail.com, geoPoint lat: 37.57444, lon: 43.74083, hasResults: False
protocolSection identificationModule nctId: NCT06315803, orgStudyIdInfo id: ChinaPLAGH20230601, briefTitle: Randomized Controlled Clinical Study of Biplanar Ultrasound-guided Puncture of Lumbar Interforamen, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-23, primaryCompletionDateStruct date: 2024-02-01, completionDateStruct date: 2024-02-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Yi Mao, class: OTHER, collaborators name: National Natural Science Foundation of China, descriptionModule briefSummary: The goal of this clinical trial is to compare Xplane ultrasound with radiography for guidance of lumbar interforamen puncture in patients with lumbar disc herniation. The main question\[s\] it aims to answer are:* The feasibility that the Xplane ultrasound assists surgeon in mastering lumbar interforamen puncture faster than radiography.* The clinical accuracy and safety of the Xplane ultrasound-guidance lumbar interforamen puncture faster.Participants will undergo lumbar interforamen puncture with guidance of Xplane ultrasound or radiography. If there is a comparison group: Researchers will compare the first success rate, number of punctures, number of radiographies, puncture time and operator confidence score., conditionsModule conditions: Lumbar Disc Herniation, conditions: Percutaneous Endoscopic Lumbar Discectomy, conditions: Three-dimension Ultrasound, conditions: Learning Curves, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: There are practical differences in operation and blind methods cannot be achieved., enrollmentInfo count: 76, type: ACTUAL, armsInterventionsModule interventions name: Real-time 3D Xplane ultrasound, outcomesModule primaryOutcomes measure: the first success rate, primaryOutcomes measure: number of punctures, primaryOutcomes measure: number of radiographies, primaryOutcomes measure: puncture time, secondaryOutcomes measure: operator confidence score, secondaryOutcomes measure: operative time, secondaryOutcomes measure: incidence of puncture relevant complications, secondaryOutcomes measure: satisfaction of patients, otherOutcomes measure: visual analog scale of pain, otherOutcomes measure: Oswestry disability index, otherOutcomes measure: modified Macnab criteria type, eligibilityModule sex: ALL, minimumAge: 16 Years, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chinese PLA General Hospital, city: Beijing, state: Beijing, zip: 100853, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06315790, orgStudyIdInfo id: TN BTX-A Trial, briefTitle: Safety and Efficacy of Botulinum Toxin A in Patients With Trigeminal Neuralgia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2025-10-01, completionDateStruct date: 2025-10-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Henrik Schytz, class: OTHER, descriptionModule briefSummary: This is a double-blind randomized clinical trial comparing the pain reduction of individuals treated with BTX-A and placebo as well as evaluating possible changes in neuroinflammatory biomarkers. The trial lasts 16 weeks, with a 4-week baseline phase and a 12-week randomization phase. Four visits are planned: 1) Introduction and baseline data collection, 2) Medical evaluation and treatment assignment, 3) Follow-up with biomarker analysis, and 4) Trial conclusion interview. 80 participants will be included and randomized 1:1., conditionsModule conditions: Trigeminal Neuralgia, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Botulinum toxin A, interventions name: Isotonic saline, outcomesModule primaryOutcomes measure: Proportion of responders in botulunim toxin A and placebo group, secondaryOutcomes measure: Biomarkers, secondaryOutcomes measure: Tear fluid CGRP, secondaryOutcomes measure: 50 % reduction, secondaryOutcomes measure: 75 % reduction, secondaryOutcomes measure: Prolonged 30 % reduction, secondaryOutcomes measure: Change in paroxysms, secondaryOutcomes measure: PGI-C, secondaryOutcomes measure: PENN Facial Pain Scale-Revised (PENN-FPS-R), secondaryOutcomes measure: Patient's guess, secondaryOutcomes measure: Dropouts, secondaryOutcomes measure: Side effects, otherOutcomes measure: Pure paroxysmal pain vs. paroxysms with concomitant pain, otherOutcomes measure: Idiopathic vs. classical trigeminal neuralgia, otherOutcomes measure: Patients with severe pain, otherOutcomes measure: Gender distribution, otherOutcomes measure: Disease duration, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Danish Headache Center, status: RECRUITING, city: Glostrup, zip: 2600, country: Denmark, contacts name: Henrik Schytz, MD, role: CONTACT, phone: +4528761824, email: henrik.winther.schytz.01@regionh.dkonh.dk, contacts name: Henrik Schytz, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 55.6666, lon: 12.40377, hasResults: False
protocolSection identificationModule nctId: NCT06315777, orgStudyIdInfo id: FRGS/1/2021/SKK01/UKM/02/1, briefTitle: GREM1, HAS2 and PTGS2 Gene Expression Following the in Vitro Maturation (IVM), statusModule overallStatus: RECRUITING, startDateStruct date: 2021-07-01, primaryCompletionDateStruct date: 2024-07-01, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: National University of Malaysia, class: OTHER, descriptionModule briefSummary: Poor ovarian reserve (POR) is an adverse prognostic factor for In-Vitro Fertilization (IVF) success. Numerous established data showed low live birth rates per IVF cycle; 6 to 10%, including the usage of In-Vitro Maturation (IVM). In Malaysia, POR incidence increases mainly from cancer survival, endometriosis, and autoimmune diseases women; therefore, IVM implementation is paramount. In the molecular level, the low competence oocytes showed a low expression of GREM1, HAS2 and PTGS2 in human cumulus cells, thus leading to poor oocyte quality(OQ). Various IVM media had been formulated to enhance the competency and quality of the oocytes to date. Therefore, our study aims to elucidate the GREM1, HAS2 and PTGS2 gene expression as oocyte developmental competency markers among POR women following IVM and tailored to the IVF outcome., conditionsModule conditions: Increased Oocyte Death, conditions: in Vitro Maturation, conditions: GREM1 Gene Mutation, conditions: Cumulus Cell, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: cumulus cell oocytes complex (COC) among women with poor ovarian reserve, outcomesModule primaryOutcomes measure: normal ovarian reserve, primaryOutcomes measure: poor ovarian reserve, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Advanced Reproductive Centre, status: RECRUITING, city: Kuala Lumpur, state: Wilayah Persekutuan Kuala Lumpur, zip: 56000, country: Malaysia, contacts name: Muhammad Azrai AA Abu, role: CONTACT, phone: +60196410944, email: azraiabu1983@gmail.com, geoPoint lat: 3.1412, lon: 101.68653, hasResults: False
protocolSection identificationModule nctId: NCT06315764, orgStudyIdInfo id: Hypertensive patients, briefTitle: Effect of the Reflexology on Insomnia Severity Index in Hypertensive Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-01, primaryCompletionDateStruct date: 2022-01-30, completionDateStruct date: 2023-05-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: In Egypt, there is a dearth of understanding of the benefits of reflexology and aerobic exercise on hypertension patients' quality of life., conditionsModule conditions: Hypertension, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Group (A):It consists of twenty female patients suffering from hypertension who underwent medical treatment as well as peddler training three times per week for eight weeks. After four weeks of treatment (post-1) and another four weeks of treatment, the post evaluation was used (post-2).Group (B):This group consisted of twenty female patients suffering from hypertension who received the same drugs as group (A) as well as reflexology three times per week for eight weeks, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 40, type: ACTUAL, armsInterventionsModule interventions name: Reflexology, outcomesModule primaryOutcomes measure: Insomnia severity index, primaryOutcomes measure: Short form 36 quality of life questionnaire (SF-36):, primaryOutcomes measure: Blood pressure measurements:, eligibilityModule sex: FEMALE, minimumAge: 35 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Heba Mousa, city: Cairo, zip: 11517, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06315751, orgStudyIdInfo id: NOE-TTS-201, briefTitle: Efficacy and Safety of Gemlapodect in Adults and Adolescents With Tourette Syndrome, acronym: Allevia2, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-31, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Noema Pharma AG, class: INDUSTRY, descriptionModule briefSummary: This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete., conditionsModule conditions: Tourette Syndrome, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Gemlapodect, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change in tic severity score on the Revised Yale Global Tic Scoring Scale (YGTSS-R), secondaryOutcomes measure: Impact on patient functioning, secondaryOutcomes measure: Change in PUTS, secondaryOutcomes measure: Safety and Tolerability of gemlapodect, secondaryOutcomes measure: Assessment of suicidality and suicidal ideation, eligibilityModule sex: ALL, minimumAge: 12 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315725, orgStudyIdInfo id: 2024-10504, briefTitle: Effect of Artificial Sweetener (AFS) on Glucose Metabolism in Patients With Type 1 Diabetes (T1D), acronym: AFS_T1D, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2025-09-01, completionDateStruct date: 2027-09-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: McGill University Health Centre/Research Institute of the McGill University Health Centre, class: OTHER, descriptionModule briefSummary: The goal of this randomized crossover study is to test the prediction that consuming carbohydrates will affect insulin release differently depending on whether Non-Nutritive Sweeteners (NNSs) are consumed simultaneously. We aim to determine whether the predicted effects are associated with oral or post-oral sweet taste receptor signaling,. Our study will focus on patients diagnosed with type 1 diabetes (T1D) who are using an artificial pancreas (AP) system, as it allows us to monitor glucose and insulin levels over time.Participants will drink four different flavored beverages, some with sweet taste blockade and some without, in a counter-balanced order. They will then rate the sweetness of each beverage, and we will collect data from their AP system to monitor insulin and glucose level.To achieve this, we will conduct a pilot study to assess the effectiveness and best timing of sweet taste blockade in healthy individuals. Insights gained from the pilot study will inform the main study.Sucralose will be used as the NNS, maltodextrin as the carbohydrate, and Gymnema Sylvestre (GS) as the sweet taste receptor blocker., conditionsModule conditions: Type 1 Diabetes (T1D), conditions: Healthy Subjects, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: OTHER, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Sweet taste perception with/without sweet taste blockade, outcomesModule primaryOutcomes measure: Effectiveness and optimal time course of sweet test blockade on sweet taste perception in healthy individuals, primaryOutcomes measure: Mean plasma glucose, basal and bolus insulin changes in individuals with T1D on AP following beverage consumption., secondaryOutcomes measure: Resting Energy Expenditure (REE) and nutrient partitioning changes in individuals with T1D on AP following beverage consumptionT1D on AP following beverage consumption, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06315712, orgStudyIdInfo id: 004201, briefTitle: Inspiratory Muscle Training in Burned Adults, acronym: Burns, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-01-15, primaryCompletionDateStruct date: 2022-06-16, completionDateStruct date: 2023-09-11, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Qassim University, class: OTHER, collaborators name: Cairo University, descriptionModule briefSummary: The study outlines burn injury impact, emphasizes need for long-term rehabilitation. Study assesses inspiratory muscle training efficacy in improving respiratory strength, lung function, and exercise capacity in adult burn patients., conditionsModule conditions: Burn Injuries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 52, type: ACTUAL, armsInterventionsModule interventions name: inspiratory exercise, interventions name: Pulmonary rehabilitation, outcomesModule primaryOutcomes measure: maximal inspiratory pressure, primaryOutcomes measure: maximal inspiratory pressure, primaryOutcomes measure: maximal expiratory pressure, primaryOutcomes measure: maximal expiratory pressure, primaryOutcomes measure: Forced expiratory volume in 1 second, primaryOutcomes measure: Forced expiratory volume in 1 second, primaryOutcomes measure: forced vital capacity, primaryOutcomes measure: forced vital capacity, primaryOutcomes measure: Forced expiratory volume in 1 second/ forced vital capacity ratio, primaryOutcomes measure: Forced expiratory volume in 1 second/ forced vital capacity ratio, secondaryOutcomes measure: Functional exercise capacity, secondaryOutcomes measure: Functional exercise capacity, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 49 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculty of Physical Therapy, Cairo University, city: Giza, state: Dokki, zip: 11432, country: Egypt, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06315699, orgStudyIdInfo id: QL000001, secondaryIdInfos id: MR-37-24-002019, type: REGISTRY, domain: Chinese Clinical Trial Registry, briefTitle: Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2025-03-02, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Qilu Hospital of Shandong University, class: OTHER, descriptionModule briefSummary: This study focuses on therapeutic targets for cognitive, motor, and social impairments in Williams syndrome by reversing brain myelin defects caused by GTF2I. The primary objective of the study was to test and evaluate the initial efficacy and safety of Clomastine fumarate in the treatment of Williams syndrome., conditionsModule conditions: Williams Syndrome, conditions: Child, conditions: Neurodevelopmental Delay, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Clemastine Fumarate Tablets, interventions name: fructose, outcomesModule primaryOutcomes measure: Anisotropy Score (FA), primaryOutcomes measure: Radial diffusion rate (RD), primaryOutcomes measure: Apparent dispersion coefficient（ADC）, primaryOutcomes measure: Magnetization transfer ratio（MTR）, primaryOutcomes measure: SRS Score 2(Social Response Scale2) score, primaryOutcomes measure: Peabody（Motion Estimation Timewarp）score, primaryOutcomes measure: Gesell Development Scale, secondaryOutcomes measure: Differential pressure across valves, secondaryOutcomes measure: Thyroid hormone value, secondaryOutcomes measure: Conners Parent Symptoms Questionnaire Score, secondaryOutcomes measure: Vailand-3 scale, secondaryOutcomes measure: CSHQ Children's Sleep Habits Questionnaire Score, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 6 Years, stdAges: CHILD, contactsLocationsModule locations facility: Qilu Hospital of Shandong University, status: RECRUITING, city: Tainan, state: Shangdong, zip: 250012, country: China, contacts name: cao aihua, role: CONTACT, phone: +18560086317, email: xinercah@163.com, contacts name: Liu zhiyue, role: CONTACT, phone: 15665785296, email: mikeydrakon8@gmail.com, hasResults: False
protocolSection identificationModule nctId: NCT06315686, orgStudyIdInfo id: MA-ENDO-202209, briefTitle: The Dynamic Monitoring of Cerebrospinal Fluid ctDNA, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-09-29, primaryCompletionDateStruct date: 2024-07-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Jiangsu Province Nanjing Brain Hospital, class: OTHER, descriptionModule briefSummary: Focusing on advanced EGFR mutation in NSCLC patients with leptomeningeal metastasis, vormetinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was used to dynamically monitor ctDNA in cerebrospinal fluid (CSF), analyze the ctDNA gene mutation profile of CSF in different patients, and explore the relationship between ctDNA and efficacy and prognosis., conditionsModule conditions: NSCLC, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: pemetrexed, outcomesModule primaryOutcomes measure: The progression-free survival time（PFS）, secondaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nanjing Brain Hospital, status: RECRUITING, city: Suzhou, state: Jiangsu, zip: 210029, country: China, contacts name: fang S Cun, M.D., role: CONTACT, phone: 83728558, phoneExt: 025, email: fang1984@aliyun.com, contacts name: fang S cun, role: CONTACT, phone: 83728558, email: fang1984@aliyun.com, geoPoint lat: 31.30408, lon: 120.59538, hasResults: False